Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Neurology and Therapy
Published in: Neurology and Therapy 2/2019

Open Access 01-12-2019 | Alzheimer's Disease | Review

Reflections on the Utility of the Retina as a Biomarker for Alzheimer’s Disease: A Literature Review

Authors: Jennifer Ngolab, Patrick Honma, Robert A. Rissman

Published in: Neurology and Therapy | Special Issue 2/2019

Login to get access

Abstract

As a part of the central nervous system, the retina may reflect both physiologic processes and abnormalities related to diseases of the brain. Indeed, a concerted effort has been put forth to understand how Alzheimer’s disease (AD) pathology may manifest in the retina as a means to assess the state of the AD brain. The development and refinement of ophthalmologic techniques for studying the retina in vivo have produced evidence of retinal degeneration in AD diagnosed patients. In this review, we will discuss retinal imaging techniques implemented to study the changes in AD retina as well as highlight the recent efforts made to correlate such findings to other clinical hallmarks of AD to assess the viability of the retina as a biomarker for AD.
Literature
1.
Roher AE, Kokjohn TA, Clarke SG, Sierks MR, Maarouf CL, Serrano GE, et al. APP/Aβ structural diversity and Alzheimer’s disease pathogenesis. Neurochem Int. 2017;110:1–13.PubMedPubMedCentralCrossRef
2.
3.
Jack CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:257–62.PubMedCrossRef
4.
Katz B, Rimmer S, Iragui V, Katzman R. Abnormal pattern electroretinogram in Alzheimer’s disease: evidence for retinal ganglion cell degeneration? Ann Neurol. 1989;26:221–5.PubMedCrossRef
5.
Lee AG, Martin CO. Neuro-ophthalmic findings in the visual variant of Alzheimer’s disease. Ophthalmology. 2004;111:376–80.PubMedCrossRef
6.
Mendez MF, Cherrier MM, Meadows RS. Depth perception in Alzheimer’s disease. Percept Mot Skills. 1996;83:987–95.PubMedCrossRef
7.
8.
Gilmore GC, Whitehouse PJ. Contrast sensitivity in Alzheimer’s disease: a 1-year longitudinal analysis. Optom Vis Sci. 1995;72:83–91.PubMedCrossRef
9.
Blanks JC, Hinton DR, Sadun AA, Miller CA. Retinal ganglion cell degeneration in Alzheimer’s disease. Brain Res. 1989;501:364–72.PubMedCrossRef
10.
11.
Sinn R, Wittbrodt J. An eye on eye development. Neural Develop. 2013;130:347–58.
12.
London A, Benhar I, Schwartz M. The retina as a window to the brain—from eye research to CNS disorders. Nat Rev Neurol. 2013;9:44–53.PubMedCrossRef
13.
Nguyen CTO, Hui F, Charng J, Velaedan S, van Koeverden AK, Lim JKH, et al. Retinal biomarkers provide “insight” into cortical pharmacology and disease. Pharmacol Ther. 2017;175:151–77.PubMedCrossRef
14.
Du LY, Chang LYL, Ardiles AO, Tapia-Rojas C, Araya J, Inestrosa NC, et al. Alzheimer’s disease-related protein expression in the retina of octodon degus. PLOS One. 2015;10:e0135499.PubMedPubMedCentralCrossRef
15.
Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, et al. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage. 2011;54:S204–17.PubMedCrossRef
16.
Perez SE, Lumayag S, Kovacs B, Mufson EJ, Xu S. β-amyloid deposition and functional impairment in the retina of the APPswe/PS1ΔE9 transgenic mouse model of Alzheimer’s disease. Investig Opthalmol Vis Sci. 2009;50:793.CrossRef
17.
Le Cudennec C, Faure A, Ly M, Delatour B. One-year longitudinal evaluation of sensorimotor functions in APP751SL transgenic mice. Genes Brain Behav. 2008;7:83–91.PubMedCrossRef
18.
Hale G, Good M. Impaired visuospatial recognition memory but normal object novelty detection and relative familiarity judgments in adult mice expressing the APPswe Alzheimer’s disease mutation. Behav Neurosci. 2005;119:884–91.PubMedCrossRef
19.
Ning A, Cui J, To E, Ashe KH, Matsubara J. Amyloid-β deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Investig Opthalmol Vis Sci. 2008;49:5136.CrossRef
20.
Edwards MM, Rodríguez JJ, Gutierrez-Lanza R, Yates J, Verkhratsky A, Lutty GA. Retinal macroglia changes in a triple transgenic mouse model of Alzheimer’s disease. Exp Eye Res. 2014;127:252–60.PubMedPubMedCentralCrossRef
21.
Liu B, Rasool S, Yang Z, Glabe CG, Schreiber SS, Ge J, et al. Amyloid-peptide vaccinations reduce β-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer’s transgenic mice. Am J Pathol. 2009;175:2099–110.PubMedPubMedCentralCrossRef
22.
Williams PA, Thirgood RA, Oliphant H, Frizzati A, Littlewood E, Votruba M, et al. Retinal ganglion cell dendritic degeneration in a mouse model of Alzheimer’s disease. Neurobiol Aging. 2013;34:1799–806.PubMedCrossRef
23.
Gupta VK, Chitranshi N, Gupta VB, Golzan M, Dheer Y, Wall RV, et al. Amyloid β accumulation and inner retinal degenerative changes in Alzheimer’s disease transgenic mouse. Neurosci Lett. 2016;623:52–6.PubMedCrossRef
24.
25.
Kergoat H, Kergoat M-J, Justino L, Chertkow H, Robillard A, Bergman H. An evaluation of the retinal nerve fiber layer thickness by scanning laser polarimetry in individuals with dementia of the Alzheimer type. Acta Ophthalmol Scand. 2001;79:187–91.PubMedCrossRef
26.
Hedges TR, Galves RP, Speigelman D, Barbas NR, Peli E, Yardley CJ. Retinal nerve fiber layer abnormalities in Alzheimer’s disease. Acta Ophthalmol Scand. 2009;74:271–5.CrossRef
27.
Tsai CS, Ritch R, Schwartz B, Lee SS, Miller NR, Chi T, et al. Optic nerve head and nerve fiber layer in Alzheimer’s disease. Arch Ophthalmol Chic Ill. 1960;1991(109):199–204.
28.
Tuulonen A, Lehtola J, Airaksinen PJ. Nerve fiber layer defects with normal visual fields. Do normal optic disc and normal visual field indicate absence of glaucomatous abnormality? Ophthalmology. 1993;100:587–97 (discussion 597–598).PubMedCrossRef
29.
Soliman MAE, Van Den Berg TJTP, Ismaeil AAA, De Jong LAMS, De Smet MD. Retinal nerve fiber layer analysis: relationship between optical coherence tomography and red-free photography. Am J Ophthalmol. 2002;133:187–95.PubMedCrossRef
30.
31.
Polo V, Garcia-Martin E, Bambo MP, Pinilla J, Larrosa JM, Satue M, et al. Reliability and validity of Cirrus and Spectralis optical coherence tomography for detecting retinal atrophy in Alzheimer’s disease. Eye. 2014;28:680–90.PubMedPubMedCentralCrossRef
32.
33.
Chan VTT, Sun Z, Tang S, Chen LJ, Wong A, Tham CC, et al. Spectral-domain OCT measurements in Alzheimer’s disease. Ophthalmology. 2019;126:497–510.PubMedCrossRef
34.
Thomson KL, Yeo JM, Waddell B, Cameron JR, Pal S. A systematic review and meta-analysis of retinal nerve fiber layer change in dementia, using optical coherence tomography. Alzheimers Dement Diagn Assess Dis Monit. 2015;1:136–43.
35.
den Haan J, Verbraak FD, Visser PJ, Bouwman FH. Retinal thickness in Alzheimer’s disease: a systematic review and meta-analysis. Alzheimers Dement Amst Neth. 2017;6:162–70.CrossRef
36.
Coppola G, Di Renzo A, Ziccardi L, Martelli F, Fadda A, Manni G, et al. Optical coherence tomography in Alzheimer’s disease: a meta-analysis. PLoS One. 2015;10:e0134750.PubMedPubMedCentralCrossRef
37.
He X-F, Liu Y-T, Peng C, Zhang F, Zhuang S, Zhang J-S. Optical coherence tomography assessed retinal nerve fiber layer thickness in patients with Alzheimer’s disease: a meta-analysis. Int J Ophthalmol. 2012;5:401–5.PubMedPubMedCentral
38.
Shi Z, Zhu Y, Wang M, Wu Y, Cao J, Li C, et al. The utilization of retinal nerve fiber layer thickness to predict cognitive deterioration. J Alzheimers Dis. 2015;49:399–405.CrossRef
39.
40.
Bambo MP, Garcia-Martin E, Pinilla J, Herrero R, Satue M, Otin S, et al. Detection of retinal nerve fiber layer degeneration in patients with Alzheimer’s disease using optical coherence tomography: searching new biomarkers. Acta Ophthalmol (Copenh). 2014;92:e581–2.CrossRef
41.
Trebbastoni A, D’Antonio F, Bruscolini A, Marcelli M, Cecere M, Campanelli A, et al. Retinal nerve fibre layer thickness changes in Alzheimer’s disease: results from a 12-month prospective case series. Neurosci Lett. 2016;629:165–70.PubMedCrossRef
42.
Iseri PK, Altinas O, Tokay T, Yuksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol. 2006;26:18–24.PubMedCrossRef
43.
Cheung CY, Ong YT, Hilal S, Ikram MK, Low S, Ong YL, et al. Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis. 2015;45:45–56.PubMedCrossRef
44.
Kesler A, Vakhapova V, Korczyn AD, Naftaliev E, Neudorfer M. Retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Clin Neurol Neurosurg. 2011;113:523–6.PubMedCrossRef
45.
Garcia-Martin E, Bambo MP, Marques ML, Satue M, Otin S, Larrosa JM, et al. Ganglion cell layer measurements correlate with disease severity in patients with Alzheimer’s disease. Acta Ophthalmol (Copenh). 2016;94:e454–9.CrossRef
46.
Gao L, Liu Y, Li X, Bai Q, Liu P. Abnormal retinal nerve fiber layer thickness and macula lutea in patients with mild cognitive impairment and Alzheimer’s disease. Arch Gerontol Geriatr. 2015;60:162–7.PubMedCrossRef
47.
Moschos MM, Markopoulos I, Chatziralli I, Rouvas A, Papageorgiou SG, Ladas I, et al. Structural and functional impairment of the retina and optic nerve in Alzheimer’s disease. Curr Alzheimer Res. 2012;9:782–8.PubMedCrossRef
48.
Lu Y, Li Z, Zhang X, Ming B, Jia J, Wang R, et al. Retinal nerve fiber layer structure abnormalities in early Alzheimer’s disease: evidence in optical coherence tomography. Neurosci Lett. 2010;480:69–72.PubMedCrossRef
49.
50.
Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL. Retinal abnormalities in early Alzheimer’s disease. Investig Opthalmology Vis Sci. 2007;48:2285.CrossRef
51.
Cunha JP, Proença R, Dias-Santos A, Almeida R, Águas H, Alves M, et al. OCT in Alzheimer’s disease: thinning of the RNFL and superior hemiretina. Graefes Arch Clin Exp Ophthalmol. 2017;255:1827–35.PubMedCrossRef
52.
La Morgia C, Ross-Cisneros FN, Koronyo Y, Hannibal J, Gallassi R, Cantalupo G, et al. Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol. 2015;79:90–109.PubMedPubMedCentralCrossRef
53.
Kwon JY, Yang JH, Han JS, Kim DG. Analysis of the retinal nerve fiber layer thickness in Alzheimer disease and mild cognitive impairment. Korean J Ophthalmol. 2017;31:548.PubMedPubMedCentralCrossRef
54.
Kirbas S, Turkyilmaz K, Anlar O, Tufekci A, Durmus M. Retinal nerve fiber layer thickness in patients with Alzheimer disease. J Neuro-Ophthalmol. 2013;33:58–61.CrossRef
55.
Eraslan M, Cerman E, Cekic O, Balci S, Dericioglu V, Sahin O, et al. Neurodegeneration in ocular and central nervous systems: optical coherence tomography study in normal-tension glaucoma and Alzheimer disease. Turk J Med Sci. 2015;45:1106–14.PubMedCrossRef
56.
Chi Y, Wang Y, Yang L. The investigation of retinal nerve fiber loss in Alzheimer’s disease. Zhonghua Yan Ke Za Zhi Chin J Ophthalmol. 2010;46:134–9.
57.
58.
Blanks JC, Torigoe Y, Hinton DR, Blanks RHI. Retinal pathology in Alzheimer’s disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging. 1996;17:377–84.PubMedCrossRef
59.
Marziani E, Pomati S, Ramolfo P, Cigada M, Giani A, Mariani C, et al. Evaluation of retinal nerve fiber layer and ganglion cell layer thickness in Alzheimer’s disease using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2013;54:5953–8.PubMedCrossRef
60.
den Haan J, Janssen SF, van de Kreeke JA, Scheltens P, Verbraak FD, Bouwman FH. Retinal thickness correlates with parietal cortical atrophy in early-onset Alzheimer’s disease and controls. Alzheimers Dement Diagn Assess Dis Monit. 2018;10:49–55.
61.
Feke GT, Hyman BT, Stern RA, Pasquale LR. Retinal blood flow in mild cognitive impairment and Alzheimer’s disease. Alzheimers Dement Diagn Assess Dis Monit. 2015;1:144–51.
62.
Pillai JA, Bermel R, Bonner-Jackson A, Rae-Grant A, Fernandez H, Bena J, et al. Retinal nerve fiber layer thinning in Alzheimer’s disease. Am J Alzheimers Dis Dementiasr. 2016;31:430–6.CrossRef
63.
Gharbiya M, Trebbastoni A, Parisi F, Manganiello S, Cruciani F, D’Antonio F, et al. Choroidal thinning as a new finding in Alzheimer’s disease: evidence from enhanced depth imaging spectral domain optical coherence tomography. J Alzheimers Dis. 2014;40:907–17.PubMedCrossRef
64.
Salobrar-Garcia E, Hoyas I, Leal M, de Hoz R, Rojas B, Ramirez AI, et al. Analysis of retinal peripapillary segmentation in Early Alzheimer’s disease patients. Biomed Res Int. 2015;2015:8.CrossRef
65.
Sanchez D, Castilla-Marti M, Rodriguez-Gomez O, Valero S, Piferrer A, Martinez G, et al. Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer’s disease. Sci Rep. 2018;8:16345.PubMedPubMedCentralCrossRef
66.
Lad EM, Mukherjee D, Stinnett SS, Cousins SW, Potter GG, Burke JR, et al. Evaluation of inner retinal layers as biomarkers in mild cognitive impairment to moderate Alzheimer’s disease. PLoS One. 2018;13:e0192646.PubMedPubMedCentralCrossRef
67.
Forte R, Cennamo GL, Finelli ML, de Crecchio G. Comparison of time domain Stratus OCT and spectral domain SLO/OCT for assessment of macular thickness and volume. Eye. 2009;23:2071–8.PubMedCrossRef
68.
Zabel P, Kałużny JJ, Wiłkość-Dębczyńska M, Gębska-Tołoczko M, Suwała K, Kucharski R, et al. Peripapillary retinal nerve fiber layer thickness in patients with Alzheimer’s disease: a comparison of eyes of patients with Alzheimer’s disease, primary open-angle glaucoma, and preperimetric glaucoma and healthy controls. Med Sci Monit. 2019;25:1001–8.PubMedPubMedCentralCrossRef
69.
70.
Cacabelos R, Fernandez-Novoa L, Lombardi V, Corzo L, Pichel V, Kubota Y. Cerebrovascular risk factors in Alzheimer’s disease: brain hemodynamics and pharmacogenomic implications. Neurol Res. 2003;25:567–80.PubMedCrossRef
71.
Sabayan B, Jansen S, Oleksik AM, van Osch MJP, van Buchem MA, van Vliet P, et al. Cerebrovascular hemodynamics in Alzheimer’s disease and vascular dementia: a meta-analysis of transcranial Doppler studies. Ageing Res Rev. 2012;11:271–7.PubMedCrossRef
72.
Patton N, Aslam T, MacGillivray T, Pattie A, Deary IJ, Dhillon B. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. J Anat. 2005;206:319–48.PubMedPubMedCentralCrossRef
73.
Pérez MA, Bruce BB, Newman NJ, Biousse V. The use of retinal photography in nonophthalmic settings and its potential for neurology. Neurologist. 2012;18:350–5.PubMedPubMedCentralCrossRef
74.
75.
Baker ML, Marino Larsen EK, Kuller LH, Klein R, Klein BE, Siscovick DS, et al. Retinal microvascular signs, cognitive function, and dementia in older persons. Stroke. 2007;38:2041–7.PubMedCrossRef
76.
de Jong FJ, Schrijvers EMC, Ikram MK, Koudstaal PJ, de Jong PTVM, Hofman A, et al. Retinal vascular caliber and risk of dementia: the Rotterdam study. Neurology. 2011;76:816–21.PubMedPubMedCentralCrossRef
77.
Shaun F, Alauddin B, David O, James DD, Lance Macaulay S, Hamid RS, et al. Modulation of retinal arteriolar central reflection by APOE genotype. Curr Alzheimer Res. 2017;14:916–23.
78.
Jung N-Y, Han JC, Ong YT, Cheung CY, Chen CP, Wong TY, et al. Retinal microvasculature changes in amyloid-negative subcortical vascular cognitive impairment compared to amyloid-positive Alzheimer’s disease. J Neurol Sci. 2019;396:94–101.PubMedCrossRef
79.
Provenzano FA, Muraskin J, Tosto G, Narkhede A, Wasserman BT, Griffith EY, et al. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol. 2013;70:455–61.PubMedPubMedCentralCrossRef
80.
Martin Dichgans, Didier Leys. Vascular cognitive impairment. Circ Res. 2017;120:573–91.CrossRef
81.
McGrory S, Cameron JR, Pellegrini E, Warren C, Doubal FN, Deary IJ, et al. The application of retinal fundus camera imaging in dementia: a systematic review. Alzheimers Dement Diagn Assess Dis Monit. 2017;6:91–107.
82.
Cheung CY, Ong YT, Ikram MK, Ong SY, Li X, Hilal S, et al. Microvascular network alterations in the retina of patients with Alzheimer’s disease. Alzheimers Dement. 2014;10:135–42.PubMedCrossRef
83.
Williams MA, McGowan AJ, Cardwell CR, Cheung CY, Craig D, Passmore P, et al. Retinal microvascular network attenuation in Alzheimer’s disease. Alzheimers Dement Diagn Assess Dis Monit. 2015;1:229–35.
84.
Campbell JP, Zhang M, Hwang TS, Bailey ST, Wilson DJ, Jia Y, et al. Detailed vascular anatomy of the human retina by projection-resolved optical coherence tomography angiography. Sci Rep. 2017;7:42201.PubMedPubMedCentralCrossRef
85.
Spaide RF, Klancnik JM Jr, Cooney MJ. Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography. JAMA Ophthalmol. 2015;133:45–50.PubMedCrossRef
86.
Koustenis AJ, Harris A, Gross J, Januleviciene I, Shah A, Siesky B. Optical coherence tomography angiography: an overview of the technology and an assessment of applications for clinical research. Br J Ophthalmol. 2017;101:16–20.PubMedCrossRef
87.
Lahme L, Esser EL, Mihailovic N, Schubert F, Lauermann J, Johnen A, et al. Evaluation of ocular perfusion in Alzheimer’s disease using optical coherence tomography angiography. J Alzheimers Dis. 2018;66:1745–52.PubMedCrossRef
88.
Jiang H, Wei Y, Shi Y, Wright CB, Sun X, Gregori G, et al. Altered macular microvasculature in mild cognitive impairment and Alzheimer disease. J Neuro-Ophthalmol. 2018;38:292–8.CrossRef
89.
Grewal DS, Polascik BW, Hoffmeyer GC, Fekrat S. Assessment of differences in retinal microvasculature using OCT angiography in Alzheimer’s disease: a twin discordance report. Ophthalmic Surg Lasers Imaging Retina. 2018;49:440–4.PubMedCrossRef
90.
Bulut M, Kurtuluş F, Gözkaya O, Erol MK, Cengiz A, Akıdan M, et al. Evaluation of optical coherence tomography angiographic findings in Alzheimer’s type dementia. Br J Ophthalmol. 2017;102:233–7.PubMedCrossRef
91.
Zhang YS, Zhou N, Knoll BM, Samra S, Ward MR, Weintraub S, et al. Parafoveal vessel loss and correlation between peripapillary vessel density and cognitive performance in amnestic mild cognitive impairment and early Alzheimer’s Disease on optical coherence tomography angiography. PLoS One. 2019;14:e0214685.PubMedPubMedCentralCrossRef
92.
Nielsen RB, Egefjord L, Angleys H, Mouridsen K, Gejl M, Møller A, et al. Capillary dysfunction is associated with symptom severity and neurodegeneration in Alzheimer’s disease. Alzheimers Dement. 2017;13:1143–53.PubMedCrossRef
93.
94.
95.
Bresnick GH, Condit R, Syrjala S, Palta M, Groo A, Korth K. Abnormalities of the foveal avascular zone in diabetic retinopathy. JAMA Ophthalmol. 1984;102:1286–93.
96.
O’Bryhim BE, Apte RS, Kung N, Coble D, Van Stavern GP. Association of preclinical Alzheimer disease with optical coherence tomographic angiography findings. JAMA Ophthalmol. 2018;136:1242.PubMedPubMedCentralCrossRef
97.
van de Kreeke JA, Nguyen H-T, Konijnenberg E, Tomassen J, den Braber A, ten Kate M, et al. Optical coherence tomography angiography in preclinical Alzheimer’s disease. Br J Ophthalmol. 2019;bjophthalmol-2019-314127.
98.
Bhat AH, Dar KB, Anees S, Zargar MA, Masood A, Sofi MA, et al. Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight. Biomed Pharmacother. 2015;74:101–10.PubMedCrossRef
99.
Stefánsson E, Olafsdottir OB, Eliasdottir TS, Vehmeijer W, Einarsdottir AB, Bek T, et al. Retinal oximetry: metabolic imaging for diseases of the retina and brain. Prog Retin Eye Res. 2019;70:1–22.PubMedCrossRef
100.
101.
Einarsdottir AB, Hardarson SH, Kristjansdottir JV, Bragason DT, Snaedal J, Stefánsson E. Retinal oximetry imaging in Alzheimer’s disease. J Alzheimers Dis. 2015;49:79–83.CrossRef
102.
Olafsdottir OB, Saevarsdottir HS, Hardarson SH, Hannesdottir KH, Traustadottir VD, Karlsson RA, et al. Retinal oxygen metabolism in patients with mild cognitive impairment. Alzheimers Dement Diagn Assess Dis Monit. 2018;10:340–5.
103.
104.
105.
Mwanza J-C, Chang RT, Budenz DL, Durbin MK, Gendy MG, Shi W, et al. Reproducibility of peripapillary retinal nerve fiber layer thickness and optic nerve head parameters measured with cirrus HD-OCT in glaucomatous eyes. Invest Ophthalmol Vis Sci. 2010;51:5724–30.PubMedPubMedCentralCrossRef
106.
Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A. Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet. 2014;15:151–71.PubMedPubMedCentralCrossRef
107.
Csincsik L, MacGillivray TJ, Flynn E, Pellegrini E, Papanastasiou G, Barzegar-Befroei N, et al. Peripheral retinal imaging biomarkers for Alzheimer’s disease: a pilot study. Ophthalmic Res. 2018;59:182–92.PubMedCrossRef
108.
Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV. Characterization of β amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res. 2004;78:243–56.PubMedCrossRef
109.
Dentchev T, Milam AH, Lee VMY, Trojanowski JQ, Dunaief JL. Amyloid-β is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. In: Hans E, Grossniklaus MD (eds) Am J Ophthalmol. 2003;136:787.
110.
Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer’s A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA. 2002;99:11830–5.PubMedPubMedCentralCrossRef
111.
Brandl C, Brücklmayer C, Günther F, Zimmermann ME, Küchenhoff H, Helbig H, et al. Retinal layer thicknesses in early age-related macular degeneration: results from the german AugUR study. Invest Ophthalmol Vis Sci. 2019;60:1581–94.PubMedPubMedCentralCrossRef
112.
Schuman SG, Koreishi AF, Farsiu S, Jung S, Izatt JA, Toth CA. Photoreceptor layer thinning over drusen in eyes with age-related macular degeneration imaged in vivo with spectral-domain optical coherence tomography. Ophthalmology. 2009;116(488–496):e2.
113.
Sadigh S, Cideciyan AV, Sumaroka A, Huang WC, Luo X, Swider M, et al. Abnormal thickening as well as thinning of the photoreceptor layer in intermediate age-related macular degeneration. Invest Ophthalmol Vis Sci. 2013;54:1603–12.PubMedCrossRef
114.
Uchida A, Pillai JA, Bermel R, Bonner-Jackson A, Rae-Grant A, Fernandez H, et al. Outer retinal assessment using spectral-domain optical coherence tomography in patients with Alzheimer’s and Parkinson’s disease. Invest Ophthalmol Vis Sci. 2018;59:2768–77.PubMedPubMedCentralCrossRef
115.
Mancino R, Martucci A, Cesareo M, Giannini C, Corasaniti MT, Bagetta G, et al. Glaucoma and Alzheimer disease: one age-related neurodegenerative disease of the brain. Curr Neuropharmacol. 2018;16:971–7.PubMedPubMedCentralCrossRef
116.
McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, Merges CA, Pease ME, Kerrigan DF, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002;43:1077–87.PubMed
117.
118.
Gupta N, Fong J, Ang LC, Yücel YH. Retinal tau pathology in human glaucomas. Can J Ophthalmol. 2008;43:53–60.PubMedCrossRef
119.
Yoneda S, Hara H, Hirata A, Fukushima M, Inomata Y, Tanihara H. Vitreous fluid levels of beta-amyloid (1–42) and tau in patients with retinal diseases. Jpn J Ophthalmol. 2005;49:106–8.PubMedCrossRef
120.
Cesareo M, Martucci A, Ciuffoletti E, Mancino R, Cerulli A, Sorge RP, et al. Association between Alzheimer’s disease and glaucoma: a study based on Heidelberg retinal tomography and frequency doubling technology perimetry. Front Neurosci. 2015;9:479.PubMedPubMedCentralCrossRef
121.
Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloidin vivo. J Biol Chem. 2004;280:5892–901.PubMedCrossRef
122.
123.
Williams EA, McGuone D, Frosch MP, Hyman BT, Laver N, Stemmer-Rachamimov A. Absence of Alzheimer disease neuropathologic changes in eyes of subjects with Alzheimer disease. J Neuropathol Exp Neurol. 2017;76:376–83.PubMedPubMedCentralCrossRef
124.
Schön C, Hoffmann NA, Ochs SM, Burgold S, Filser S, Steinbach S, et al. Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS One. 2012;7:e53547.PubMedPubMedCentralCrossRef
125.
Ho C-Y, Troncoso JC, Knox D, Stark W, Eberhart CG. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer’s and Parkinson’s disease patients. Brain Pathol. 2013;24:25–32.PubMedPubMedCentralCrossRef
126.
Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer’s disease. N Engl J Med. 1986;315:485–7.PubMedCrossRef
127.
Leger F, Fernagut P-O, Canron M-H, Léoni S, Vital C, Tison F, et al. Protein aggregation in the aging retina. J Neuropathol Exp Neurol. 2011;70:63–8.PubMedCrossRef
128.
129.
Ong SS, Doraiswamy PM, Lad EM. Controversies and future directions of ocular biomarkers in Alzheimer disease. JAMA Neurol. 2018;75:650.PubMedCrossRef
130.
131.
132.
Sadda SR, Borrelli E, Fan W, Ebraheem A, Marion KM, Harrington M, et al. A pilot study of fluorescence lifetime imaging ophthalmoscopy in preclinical Alzheimer’s disease. Eye Lond Engl. 2019;33:1271–9.
133.
Jentsch S, Schweitzer D, Schmidtke K-U, Peters S, Dawczynski J, Bar K-J, et al. Retinal fluorescence lifetime imaging ophthalmoscopy measures depend on the severity of Alzheimer’s disease. Acta Ophthalmol (Copenh). 2015;93:e241–7.CrossRef
134.
135.
Wei Y, Jiang H, Shi Y, Qu D, Gregori G, Zheng F, et al. Age-related alterations in the retinal microvasculature, microcirculation, and microstructure. Invest Ophthalmol Vis Sci. 2017;58:3804–17.PubMedPubMedCentralCrossRef
136.
Lin Y, Jiang H, Liu Y, Rosa Gameiro G, Gregori G, Dong C, et al. Age-related alterations in retinal tissue perfusion and volumetric vessel density. Invest Ophthalmol Vis Sci. 2019;60:685–93.PubMedPubMedCentralCrossRef
137.
Iafe NA, Phasukkijwatana N, Chen X, Sarraf D. Retinal capillary density and foveal avascular zone area are age-dependent: quantitative analysis using optical coherence tomography angiography. Invest Ophthalmol Vis Sci. 2016;57:5780–7.PubMedCrossRef
138.
Ooto S, Vongkulsiri S, Sato T, Suzuki M, Curcio CA, Spaide RF. Outer retinal corrugations in age-related macular degeneration. JAMA Ophthalmol. 2014;132:806–13.PubMedCrossRef
139.
Karampelas M, Sim DA, Keane PA, Papastefanou VP, Sadda SR, Tufail A, et al. Evaluation of retinal pigment epithelium–Bruch’s membrane complex thickness in dry age-related macular degeneration using optical coherence tomography. Br J Ophthalmol. 2013;97:1256.PubMedCrossRef
140.
Santos CY, Johnson LN, Sinoff SE, Festa EK, Heindel WC, Snyder PJ. Change in retinal structural anatomy during the preclinical stage of Alzheimer’s disease. Alzheimers Dement Diagn Assess Dis Monit. 2018;10:196–209.
141.
den Haan J, van de Kreeke JA, van Berckel BN, Barkhof F, Teunissen CE, Scheltens P, et al. Is retinal vasculature a biomarker in amyloid proven Alzheimer’s disease? Alzheimers Dement Diagn Assess Dis Monit. 2019;11:383–91.
142.
Frost S, Kanagasingam Y, Sohrabi H, Vignarajan J, Bourgeat P, Salvado O, et al. Retinal vascular biomarkers for early detection and monitoring of Alzheimer’s disease. Transl Psychiatry. 2013;3:e233.PubMedPubMedCentralCrossRef
143.
Sousa DC, Leal I, Moreira S, Dionísio P, Abegão Pinto L, Marques-Neves C. Hypoxia challenge test and retinal circulation changes—a study using ocular coherence tomography angiography. Acta Ophthalmol (Copenh). 2018;96:e315–9.CrossRef
144.
Marchesi VT. Alzheimer’s dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J. 2011;25:5–13.PubMedCrossRef
145.
Grimaldi A, Brighi C, Peruzzi G, Ragozzino D, Bonanni V, Limatola C, et al. Inflammation, neurodegeneration and protein aggregation in the retina as ocular biomarkers for Alzheimer’s disease in the 3xTg-AD mouse model. Cell Death Dis. 2018;9:685.PubMedPubMedCentralCrossRef
146.
Knoll B, Simonett J, Volpe NJ, Farsiu S, Ward M, Rademaker A, et al. Retinal nerve fiber layer thickness in amnestic mild cognitive impairment: case-control study and meta-analysis. Alzheimers Dement Amst Neth. 2016;4:85–93.CrossRef
Metadata
Title
Reflections on the Utility of the Retina as a Biomarker for Alzheimer’s Disease: A Literature Review
Authors
Jennifer Ngolab
Patrick Honma
Robert A. Rissman
Publication date
01-12-2019
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue Special Issue 2/2019
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-019-00173-4

Other articles of this Special Issue 2/2019

Neurology and Therapy 2/2019 Go to the issue

Review

Neurophysiological Markers of Alzheimer’s Disease: Quantitative EEG Approach

Review

Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment

Review

A Review on MS-Based Blood Biomarkers for Alzheimer’s Disease

Review

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Editorial

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress

Review

Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology